Literature DB >> 26765550

The impact of a dedicated patent ductus arteriosus ligation team on neonatal health-care outcomes.

M H F Resende1, K More1, D Nicholls1, J Ting2, A Jain3, P J McNamara1,4,5.   

Abstract

OBJECTIVE: The decision to perform patent ductus arteriosus (PDA) ligation is controversial. Patient selection is oftentimes poorly standardized, leading to delays in referral and inappropriate intervention. A system for PDA ligation categorization and triaging process was introduced in 2006 at a quaternary hospital in Canada to streamline referrals and enhance perioperative care. We aimed to evaluate the impact of this dedicated PDA ligation triaging system comparing pre- and postimplementation of this system. STUDY
DESIGN: We performed a retrospective chart review. Demographic and cardiorespiratory data of neonates ⩽30 weeks gestation age at birth, who were referred for and/or had a PDA ligation performed during two distinct epochs (EPOCH 1 (2003 to 2005) and EPOCH 2 (2010 to 2012)), were analyzed. All surgeries were performed at The Hospital for Sick Children, the regional referral center for PDA ligation. The primary outcome was incidence of PDA ligation and procedural cancellations. Secondary outcomes included postoperative need for cardiovascular or respiratory support. Subgroup analysis was performed in neonates <1000 vs >1000 g at the time of surgery during both epochs. RESULT: A total of 198 neonates underwent surgery with no difference in baseline demographics between epochs. The incidence of PDA ligation as a proportion of total live births under 30 weeks in Central East Region of Ontario was lower in the second epoch (EPOCH 1: 117/1092 (10.7%) vs EPOCH 2: 81/1520 (5.3%)). During the second epoch, 24% of referrals for surgery were canceled after review by our PDA ligation team. There were no overall differences in the proportion of neonates with oxygenation failure, ventilation failure or Post-Ligation Cardiac Syndrome (PLCS), after surgery, between epochs. The proportion of neonates who developed systemic hypotension was higher in patients <1000 g (n=34 (34%) vs n=17 (17.4%), P=0.01) at the time of surgery. In addition, we identified a reduction in the proportion of neonates <1000 g who developed PLCS in EPOCH 2. On the contrary, there was an increase in the proportion of neonates >1000 g who developed ventilation failure in EPOCH 2.
CONCLUSION: The presence of dedicated triaging and management system enhances efficiency of referral process through careful selection of patients for PDA ligation and optimizes perioperative management. We demonstrated a reduction in the incidence of PDA ligation without any negative impact on short-term neonatal morbidity. The use of targeted neonatal echocardiography in the assessment of PDA shunt volume and guiding postoperative decision making is likely to have contributed to these findings.

Entities:  

Mesh:

Year:  2016        PMID: 26765550     DOI: 10.1038/jp.2015.213

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  40 in total

1.  Does point-of-care functional echocardiography enhance cardiovascular care in the NICU?

Authors:  A Sehgal; P J McNamara
Journal:  J Perinatol       Date:  2008-07-17       Impact factor: 2.521

2.  Evaluation of cerebral electrical activity and cardiac output after patent ductus arteriosus ligation in preterm infants.

Authors:  A T F S Leslie; A Jain; A El-Khuffash; M Keyzers; S Rogerson; P J McNamara
Journal:  J Perinatol       Date:  2013-07-25       Impact factor: 2.521

Review 3.  The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review.

Authors:  Inge Zonnenberg; Koert de Waal
Journal:  Acta Paediatr       Date:  2011-10-06       Impact factor: 2.299

4.  Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology.

Authors:  Afif F El-Khuffash; Amish Jain; Patrick J McNamara
Journal:  J Pediatr       Date:  2013-02-11       Impact factor: 4.406

5.  Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association.

Authors:  D D Marshall; M Kotelchuck; T E Young; C L Bose; L Kruyer; T M O'Shea
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

6.  A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus.

Authors:  Martin Kluckow; Michele Jeffery; Andy Gill; Nick Evans
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-12-06       Impact factor: 5.747

7.  Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study.

Authors:  Shaul Dollberg; Ayala Lusky; Brian Reichman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-02       Impact factor: 2.839

8.  Patent ductus arteriosus ligation and post-operative hemodynamic instability: case report and framework for enhanced neonatal care.

Authors:  Arvind Sehgal; Johny Vakayil Francis; Andrew James; Patrick J McNamara
Journal:  Indian J Pediatr       Date:  2010-08-26       Impact factor: 1.967

9.  Adrenal function in preterm infants undergoing patent ductus arteriosus ligation.

Authors:  Afif EL-Khuffash; Patrick J McNamara; Anie Lapointe; Amish Jain
Journal:  Neonatology       Date:  2013-04-25       Impact factor: 4.035

10.  Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus.

Authors:  Andrea C Wickremasinghe; Elizabeth E Rogers; Robert E Piecuch; Bridget C Johnson; Suzanne Golden; Anita J Moon-Grady; Ronald I Clyman
Journal:  J Pediatr       Date:  2012-07-13       Impact factor: 4.406

View more
  1 in total

1.  Is late treatment with acetaminophen safe and effective in avoiding surgical ligation among extremely preterm neonates with persistent patent ductus arteriosus?

Authors:  Sally Mashally; Rudaina Banihani; Bonny Jasani; Lynne E Nield; Fernando F Martins; Amish Jain; Dany E Weisz
Journal:  J Perinatol       Date:  2021-08-27       Impact factor: 2.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.